Todd Villines, MD, after a recent study showed that statins’ primary prevention benefits extend beyond patients’ 85th year.

Cardiology Practices

The Disappearance of Private Practice Cardiology

In the not too distant past, the vast majority of cardiologists worked their entire careers in private practice, but a range of economic and administrative changes have driven around 70% of US cardiologists into hospital and corporate employment. In today’s issue, we’re diving into cardiology’s employment shift, and what the future holds for private practice cardiologists.

Cardiology’s private practice declines are part of a wider trend across all of medicine, with the AMA estimating that the share of US doctors in private practice dropped from 76% in the early 80s to under 47% in 2022. Meanwhile, nearly 60% of all physician practices are now under hospital or corporate ownership.

The shift away from private practice has been particularly severe within cardiology, as  estimates suggest that only 10k of the US’ 33k cardiologists remain in independent practices.

• Those practices are apparently getting smaller, with nearly 80% of independent cardiologists working in practices with under 10 physicians, and almost 40% working in single-physician practices.
• In fact, there’s now only 30 independent practices with over 50 cardiologists.
  

The shift towards corporate and hospital-owned cardiology groups doesn’t seem to be slowing down, as a long list of challenges (e.g. falling reimbursements, rising costs, administrative burdens, payor difficulties) and incentives (e.g. partners want an exit) are driving more practices to seek acquisitions by hospitals or private equity-owned groups.

• In fact, the recent emergence of private equity cardiology platforms seems to be intensifying the shift away from truly private cardiology practices.

That said, we are still seeing hospital-employed cardiology groups taking themselves private.

• Many cardiologists aren’t exactly happy with their hospital employment. Some are drawn to the lifestyle (e.g. autonomy) and/or entrepreneurial (e.g. opening ASCs) upsides of going private, and there’s now more resources available to help them make that happen.
• However, many of those cardiologists might be more likely to look for a private equity partner to help fund their shift towards “independent” practice (but not exactly private practice).

There’s also plenty of private cardiology groups who are planning to stay private, either by adding scale through organic growth or mergers with other private practices, adding new ASCs and procedural labs, or by addressing their administrative challenges through outsourcing key operations.

The Takeaway

Private practices continue to decline in cardiology and across all of US medicine, and although there are plenty of options for practices to go or stay private, it appears that this trend will continue unless we see major policy and reimbursement changes.

FFRCT Slashes PAD + CAD Mortality

See how adding HeartFlow’s FFRCT assessments to patient workups prior to peripheral artery disease surgeries can have a massive impact on coronary artery disease outcomes, including major reductions in long term heart attack and mortality risks.

Streamline Your Cardiology Imaging Workflows

See how cardiologists and their teams can streamline imaging workflows to make their cardiovascular service line more efficient, cost-effective, and patient-centered, using Merge’s cardiology solutions.

Experience the Future of Learning: Medtronic Academy 2.0 is Here!

Unlock your ultimate destination for structural heart medical education with the newly redesigned Medtronic Academy 2.0. Gain access to expert-led courses, webinars, and a wealth of resources to stay ahead in cardiovascular care. Visit now!

The Wire

• HeartFlow Plaque Matches IVUS: Results from the REVEALPLAQUE study are in, and they show that HeartFlow’s CCTA AI-based Plaque Analysis solution assesses coronary plaque similarly to IVUS, which is the reference standard. The study analyzed 237 patients (432 lesions) with HeartFlow Plaque Analysis and IVUS, finding strong agreement for total plaque volume (95%), calcified plaque volume (95%), and non-calcified plaque volume (93%). The results highlight HeartFlow Plaque Analysis’ potential for non-invasively evaluating coronary atherosclerotic burden and cardiovascular risks.

• Roche’s Lp(a) Testing Breakthrough: Roche Diagnostics’ Tina-quant lipoprotein Lp(a) RxDx assay landed FDA Breakthrough Device Designation, potentially streamlining the Lp(a) blood test’s path towards approval. Roche’s Tina-quant test was developed in partnership with Lp(a) treatment leader Amgen, and would be made available on the 90k-plus Roche serum work area systems that are currently being used worldwide.

• Digital Self-Management for Heart Patients: The largest-ever study on the use of digital tools to control risk factors for cardiovascular disease was just published in the Journal of the American Heart Association, linking Hello Heart’s app-based self-management program to significant CV outcome improvements. After examining over 100k Hello Heart users with hypertension between 2018 and 2022, those with baseline SBP above 140 mm Hg reduced their SBP by 19 mm Hg at two years, while those with baseline LDL cholesterol above 160 mg/dL reduced it by 67 mg/dL at 13 months.

• Karoo & Heartbeat Health’s VBC Alliance: Virtual cardiology practice Heartbeat Health and cardiology value-based care enablement company Karoo Health announced their partnership to launch “the first truly nationwide, end-to-end cardiac VBC solution.” The companies’ new value-based enterprise combines Karoo’s VBC-enabling AI technology and care model with Heartbeat’s virtual cardiac clinical services (clinicians, testing, and telehealth), and will be offered to payers, at-risk entities, and provider networks.

• Cardiology’s Experience-Exposure Paradox: A registry study found that early-career cardiologists tend to take on more complex PCI cases due to the “experience-exposure paradox,” resulting in “modestly worse outcomes.” In the study of more than 28M STEMI patients, early career doctors were significantly more likely than their more experienced colleagues to treat STEMI and urgent indications, and had 8% higher adjusted rates of both mortality and bleeding complications. The take-home? Early-career cardiologists could benefit from mentoring and on-the-job support from more experienced providers.

• Circle CVI Adds inHEART: Circle Cardiovascular Imaging and inHEART announced a global distribution alliance that will make inHEART’s AI-enabled “digital twin” cardiac ablation planning solution available through Circle CVI’s sales network. The partnership further expands Circle CVI’s already broad cardiovascular imaging solutions portfolio, while continuing inHEART’s busy few months, following its FDA clearance and Series A round.

• Cardurion’s PDE9 Inhibitor Progress: Cardurion Pharmaceuticals reported positive results for its PDE-9 inhibitor CRD-740 in the CARDINAL-HF Phase 2a study. Among 60 patients with HFrEF, CRD-740 met the primary endpoint with a significant increase in plasma cyclic guanosine monophosphate (cGMP) over four weeks compared to placebo. CRD-740 also improved urinary cGMP and was well-tolerated. The drug is currently being tested in two Phase 2 studies targeting HFrEF and HFpEF.

• One Chip Challenge Death: Autopsy results revealed that the Massachusetts 10th grader who died of cardiopulmonary arrest after eating an extremely spicy tortilla chip had an undiagnosed enlarged heart and congenital myocardial bridging. The teen was participating in Paqui Chips’ “One Chip Challenge,” and the chip’s high level of capsaicin (a chili pepper extract) is believed by some to have caused sudden ischemia that led to a severe (and fatal) arrhythmia.

• MCOT’s Economic Advantage: A recent study highlighted the Philips MCOT wearable ECG’s economic advantage over implantable loop recorders among post-stroke patients. Analysis of 2,244 patients found that MCOT users had significantly lower readmissions (30.2% vs. 35.4%), leading to significantly lower average per patient care costs (-$27,429). MCOT patients also had lower mortality rates (8.9% vs. 11.3%), a result that’s notable but only “bordered on significance.” 

• HF Age and Dementia Risk: A large UK Biobank study revealed higher dementia risks for people who develop heart failure at younger ages. In the study of 14.4k patients with HF and 442.8k without it, risks for all-cause dementia, vascular dementia, and Alzheimer’s were all higher per 10-year decrease in HF onset age (+18%, +64%, and +27%). All-cause dementia risk was highest for patients who developed HF before age 65 (+67%) and lowest for patients who developed HF after 75 years (+5%). 

• CLS Health Adds EP Practice: Houston area multispecialty group CLS Health expanded its cardiology capabilities to electrophysiology, merging with local practice Cardiac Rhythm Center. The acquisition comes shortly after CLS Health acquired Southeast Houston Cardiology and Clear Lake Cardiovascular Consultants, making cardiology CLS Health’s second largest service line after primary care.

Better Cardiovascular Care, With a Better Bottom Line

Twenty million chest CTs are acquired in the U.S. each year, but CAC is typically unreported. See how you can leverage Bunkerhill Health’s Incidental CAC algorithm to screen for incidental coronary calcium on routine chest CTs in real-time, improving care and your bottom line.

Reducing ECG Background Noise

Monebo’s Kinitec Rhythms ECG Algorithm separates true ECG signals from background noise, leading to more accurate diagnoses and improved operator efficiency. See for yourself how the algorithm measured up to a gold standard.

The Resource Wire

• Relieving The Burden of Post-Processing: With the advent of advanced imaging technologies like CCTA come added burdens to technologists and diagnostic imaging centers. See how PIA can relieve the burden of post-processing, saving you time while helping your bottom line.

• Where to Go for Cardio AI? TeraRecon’s Cardio Suite is a collection of hand-selected, vendor-neutral Cardiology AI algorithms that aid in the analysis and interpretation of echocardiograms and chest CTs. Learn about TeraRecon’s AI offering and how they improve efficiency and accuracy here.

• Us2.ai’s Next Gen AI: Us2.ai recently scored FDA clearance for Us2.v2, the newest version of its flagship software featuring 45 automated echocardiography parameters, including strain analysis. See how the new version automates echo exams and improves cardiovascular disease detection.

• Measuring True Cardiac Risk: How can AI help physicians “see” beyond conventional lipid profiles? Tune in to this on-demand webinar showcasing how Cleerly’s AI-QCT solution complements conventional approaches to evaluating heart disease risk factors, and improves coronary artery disease diagnosis and heart attack risk assessments.